Abstract Human milk is the best food for human infants, including those born preterm. Human milk feeding benefits the preterm infant by improving mental and motor development, decreasing the risk of necrotizing enterocolitis, sepsis, and retinopathy of prematurity during the postnatal period spent in the Neonatal Intensive Care Unit. In order to support the increased nutrient requirements of these infants, human milk must be fortified. In the absence of a mother's own milk, donor human milk is becoming a more commonly used replacement for bovine-based formula, especially in the tiniest patients. While donor human milk has been shown to convey many of the benefits of mother's own milk, it is generally lower in protein and calories than preterm milk and may require fortification in different proportions. This report discusses the evidence for donor human milk in the nutritional support of the preterm infant.
Introduction
In 2012, the American Academy of Pediatrics (AAP) reinforced its previous statement from 2006 as more research and systematic reviews affirmed that breast feeding and human milk were the reference standards for infant feeding and nutrition [1 •• ] . The many benefits of human milk versus formula include nutritional, immunologic, developmental, psychological, social, and economic. Feeding human milk to very-low-birth-weight infants has been associated with reductions in morbidity and mortality specifically related to prevention of sepsis and necrotizing enterocolitis (NEC) [2] [3] [4] [5] [6] [7] . Long-term benefits for VLBW infants from human milk include improved cognitive performance. The greatest amount of human milk as a proportion of the diet for 773 extremely preterm infants during their hospitalization in the NICU showed positive effects at 18 and 30 months of age [8] . Scores for Bayley Mental Developmental Index and Bayley behavior score percentiles for emotional regulation, and fewer hospitalizations between discharge and 30 months were observed. Remarkably, for every 10 ml/k/d increased intake of human milk, the Mental Developmental Index score increased 0.59 points. These data remained significant after adjustment for confounding factors including maternal age, education, marital status, race, and infant morbidities. The persistence of this effect out to 30 months of age from diet during the neonatal period suggested that mother's milk was a crucial therapy for VLBW infants in the NICU and after discharge. However, no donor milk was used in this study.
Neurodevelopmental outcomes at 8 years of age and through adolescence suggest that preterm infants that received human milk, including donor human milk, in the NICU had intelligence tests and white matter and total brain volumes that were greater in the subjects who had received human milk compared to those that had not [9, 10] . These neurodevelopmental outcomes are associated with predominant and not necessarily exclusive human milk feeding.
Long-term studies suggest that human milk for these infants is associated with a reduced risk for subsequent development of metabolic syndrome. Adolescents specifically had lower blood pressures if they received human milk as preterm infants and had low density lipoprotein concentrations and improved leptin and insulin metabolism, all of which are surrogates for metabolic syndrome [11, 12] . Additional studies have reported a reduction in severe retinopathy of prematurity with the use of human milk during the NICU stay [13, 14] .
Therefore, based on all these benefits and others the AAP states that all preterm infants should receive human milk [1] . Mother's own milk, fresh or frozen, should be the primary diet, and it should be fortified appropriately for the infant weighing less than 1.5 kg. If own mother's milk is unavailable despite significant lactation support, pasteurized donor milk should be used [7, 15] . Quality control of pasteurized donor milk is important and should be monitored [1] .
The demand for human milk for these infants has never been greater. There has been a renewed demand for donor human milk because of the compelling research leading to changing standards for feeding strategies for these infants. The concept of ''lacto-engineering'' has emerged where human milk components can be used to produce formulations, fortifiers, and additives to meet the nutritional needs for VLBW infants. Therefore, the supply of donor milk needs to increase to meet this demand for new, higher quality (i.e., increased protein density) products [ 
There are challenges in trying to provide exclusive human milk feedings for VLBW infants and to meet nutritional requirements. These include an inadequate supply of milk in some mothers to feed their VLBW infants, the high variability in the nutrient content of the milk, and the limitations of the milk itself to meet requirements for growth [17] [18] [19] [20] [21] . Although donor milk is preferable to bovine-based formula as a substitute for mother's own milk, both are inadequate to meet the nutritional needs for the VLBW infant without multicomponent fortification [20] .
When VLBW infants receive suboptimal nutritional support for growth, they experience postnatal growth restriction which is a surrogate for inadequate nutrition and associated with poor neurodevelopmental outcomes [22, 23] . Inadequate protein intake is mainly responsible for these untoward outcomes [22, [24] [25] [26] . Although energy is important, it plays less of a role as a cause for slow growth [21] . Therefore, if the specific deficits (primarily protein) in donor milk are even greater than in mother's own milk, it must be addressed with products that bring it in line with recommended intakes for protein and energy. This chapter will review milk banking for obtaining human milk for those infants where mothers' own milk is not available, human milk analyses to understand how to customize fortification of human milk and a review of the data supporting the use of human milk to prevent disease in VLBW infants.
Donor Human Milk: Evidence and Research Needs
Randomized controlled trials (RCTs) focusing only on pasteurized donor human milk as a sole diet are sparse because it is no longer considered appropriate to assign infants to other diets if a mother's own milk is available. Therefore, in most of our reviews, infants have been randomly assigned to human milk (mother's own or donor milk) versus formula.
Necrotizing enterocolitis (NEC) remains the most significant gastrointestinal emergency occurring among verylow-birth-weight infants. It is a major cause of morbidity and mortality, especially in extremely low-birth-weight infants who have the highest rates of the disease [27, 28] . Three systematic reviews through 2014 addressed the effect of donor human milk versus formula on clinical outcomes, especially NEC [15, 29, 30] . All three suggested a reduction in NEC in premature infants with the use of donor human milk.
McGuire and Anthony [30] reviewed four studies reported from 1982 to 1990 in which infants received donor human milk (term or preterm), standard formula, or calorie-enriched formula. While none of the four studies individually showed a statistically significant difference in the incidence of NEC, the meta-analysis did show a borderline benefit of donor milk compared to formula.
Boyd et al. published a systematic review in 2007 that included seven studies, 5 of which were from the 1970s and 1980s and some of which were also included in the Cochrane review listed below [29] . The purpose was to compare the effect of donor human milk to infant formula in preterm infants. Separate comparisons were made of the following diets: formula or donor human milk as sole diets, mother's own milk supplemented with donor milk compared to mother's own milk supplemented with formula or fortified donor milk compared to fortified formula. Donor human milk was associated with a lower risk of NEC but also slower growth in the early postnatal period. However, the authors cautioned that the quality of the evidence was limited. The sample sizes were small and these studies were over 25 years ago and unlikely to be clinically relevant to contemporary practice as the survival of VLBW infants has greatly improved. Additionally, the poor quality of randomization and masking of care givers and investigators may have biased the results.
A Cochrane review published in 2014 [15] (an update of a previous version from 2007 [31] ) considered 9 RCTs. The diet comparisons differed between the studies. Four trials compared term formula and donor human milk. Five trials compared preterm formula to donor human milk. In 3 of the 5 trials, preterm formula or donor human milk was the sole diet; in the other two trials, preterm formula or donor human milk was a supplement to maternal milk. The authors concluded that feeding formula compared with donor human milk improved short-term growth in preterm or low-birth-weight infants but doubled the risk of developing NEC. The pooled estimate suggested that an additional case of NEC would result in every 33 infants fed formula milk.
There has only been one trial in which fortified donor human milk has been compared with preterm formula [32] . In this trial, infants fed donor human milk had a slower rate of weight gain compared with preterm formula (17.1 vs. 20.1 g/kg/d; p = 0.001). Length and head circumference growth were similar in the two groups. However, infants fed exclusively with human milk had fewer episodes of late onset sepsis and/or NEC, and a shorter hospital stay.
These systematic reviews did not include a large proportion of extremely preterm infants and all except one were without fortification of the donor human milk. Additionally, formulas for preterm infants have changed significantly since those earlier studies were performed. Until a few years ago, the fortification of human milk meant the addition of bovine-based powders to human milk to provide nutritional enhancement and make the donor human milk macronutrient content more similar to preterm infant formula. Now concentrated liquid fortifiers have replaced the powders and are a sterile, purportedly, safer product. However, a consideration has been raised that exclusive human milk feeding, i.e., a species specific diet, may be important with respect to preventing NEC [7] .
A reduction in NEC, both medical and surgical, was reported over 20 years ago among infants who received an exclusive human milk diet when compared to infants \1,850 g birth weight who received all bovine-based preterm formula [33] . Infants who received formula supplementation when own mother's milk was not available had an intermediate level of protection, suggesting that exposure to bovine antigen might negate some of the benefits associated with exclusive human milk feeding. This study preceded fortification of human milk and many of the babies had growth failure.
In 2014, human milk fortifiers that are made from both bovine and concentrated human milk are available for use. Two recent studies provide a contemporary look at exclusive human milk feeding compared to human milk supplemented with bovine antigen and the risk of NEC [7, 34] .
Sullivan et al. [7] studied 207 infants 500-1,250 g birth weight whose mothers' intended to provide their own milk. Infants were randomized to an all-human milk diet (own mother's milk, donor milk supplement, human milk fortifier) or own mother's milk fortified with the bovine fortifier or supplemented with bovine-based preterm formula when own mother's milk was not available. The infants receiving the all-human milk-based diet had significantly lower rates of NEC and surgical NEC when compared with those receiving 89 % of their diet as mother's own milk and supplemented with bovine formula or fortifier. The NEC rate was 4.5 or 7 % in the exclusive human milk fortified group (fortified at 40 ml/k/d or at 100 ml/k/d) versus 16 % in the group exposed to bovine products. Surgical NEC was 1.5 % with exclusive human milk feeding compared to 12 % in those receiving the human milk-bovine supplemented diet.
Cristofalo et al. [34] studied 53 infants with mean birth weight of approximately 1,000 g and compared rates of NEC in infants receiving exclusive human milk feedings or preterm bovine formula. They found that surgical NEC was statistically significantly greater, by 16 %, in the bovine formula-fed group compared to no cases in the exclusive human milk-fed infants.
When all of the patients are included from both study groups, the background rates of NEC in the studies were higher than that seen in benchmark data from large networks and reports from many NICUs [35, 36] . The Sullivan study [7] was originally powered to evaluate days of TPN as a surrogate for feeding intolerance. However, statistical significance was reached because of the magnitude of the NEC observed in those units in the trial. It is impossible to determine whether the lower rate of NEC seen in the human milk arm was due to the benefit of the human milk fortifier or to the benefit of giving human milk as opposed to bovine fortifier and formula. The Cristofalo study [34] is small and with a very high rate of NEC (21 %) in the bovine-fed group. While some believe that an all-human milk diet is a proven strategy to prevent/reduce NEC, a recent letter to the editor of Breastfeeding Medicine [37] suggests that an unequivocal case for the use of all-human milk fortifiers has not been determined and that a definitive and appropriately powered trial needs to be done. There are other benefits related to human milk feeding but questions remain about whether donor human milk confers the same benefit as mother's own milk. For example, a number of studies from the 1980s suggest that donor human milk results in improved feeding tolerance versus formula feeding and are included in two of the discussed systematic reviews [15, 29] .
Bronchopulmonary dysplasia (BPD) and long-term neurodevelopment are two other important issues that may benefit from donor milk feedings but have limited data to review. One randomized controlled trial [32] designed to compare infection rates in infants \30 weeks' gestation observed a reduction in BPD in the infants fed fortified donor human milk compared with those fed preterm formula.
The effect of (unfortified) donor human milk on neurocognitive outcome is unknown. Only 1 randomized controlled trial has been reported [38] . This was a 3-center study from the United Kingdom with 502 preterm infants assigned to receive either unfortified donor milk or preterm formula as sole diet or as supplements to mother's own milk. There was no difference in Bayley scores between the two diet groups at 18 months of age. However, the donor milk at this time was collected by drip and thus had an energy content of *50 kcal/dL, due to the low fat content. More studies are needed for both BPD and longterm neurodevelopmental outcome using donor human milk.
Human Milk Banking
After discovery in the mid-1980s that human immunodeficiency virus (HIV) was passed into human milk, large numbers of milk banks closed. These days, human milk banks are making a comeback globally. Banks can be found in North and South America, Europe, South Africa, Australia, and Asia. Khadse and Hiremath reported in 2013 that there were 517 milk banks scattered across the world, with three quarters of the banks located in Brazil and Europe [39] . These organizations exist to be a source of safe human milk, primarily for preterm infants, whose mothers are unable to supply all the milk their infants need.
In North America, much of the donor human milk provided to hospitals comes from the members of the Human Milk Banking Association of North America (HMBANA; www.hmbana.org). These non-profit institutions receive expressed milk from unpaid volunteers that either have an abundance of milk beyond that required by their own infants or have experienced a perinatal loss. Donors are screened for a variety of transmissible infectious agents and educated in appropriate clean techniques for milk collection and storage (freezing) prior to shipping to the banks [40] . At the time of processing, milk is thawed, pooled in batches, Holder pasteurized, and cultured for bacterial growth. It is then dispensed into bottles, labeled with a batch number, and refrozen until shipped.
In addition to HMBANA, there are other organizations seeking human milk to use in research and even pharmaceuticals. Prolacta Bioscience, a venture capital company located in California (www.prolacta.com), solicits human milk donations to manufacture specialized products (human milk fortifier and other milk products) for preterm infants. The latest company to solicit human milk donations is Medolac Laboratories (Lake Oswego, OR) which works collaboratively with the Mothers Milk Cooperative (www.mothersmilk.coop).
As evidence mounts concerning the benefits of human milk, more neonatal intensive care nurseries are establishing donor milk programs for their preterm infants without mother's own milk. Simmer reported that following the establishment of a milk bank at the King Edward Memorial Hospital in Perth, Australia, the number of babies receiving donor human milk doubled in a period of 3 years [41] . Delfosse et al. reported that donor human milk was well accepted in their units as a substitute for formula in the first 2 weeks of life and did not negatively impact the subsequent availability of mother's own milk [42] . Donor human milk is a unique resource, one that is both renewable within the population of child-bearing women but constrained by any one individual's capacity to produce an excess to donate for these various purposes.
Milk Sharing
Informal sharing (purchasing) of milk either within families, by word of mouth or Internet sites but outside of a system that rigorously screens donors is of concern. Although systematic data are not readily available, Keim et al. [43 • • ] reported on a cross-sectional study of donor human milk (unpasteurized) purchased via the Internet. Three fourths of the milk samples were either positive for Gram negative bacteria or had total aerobic counts in excess of 10 4 colony-forming units/mL. One in five samples tested positive for cytomegalovirus DNA. Failure to adequately screen donors places infants at risk when being fed informally acquired, unpasteurized milk. Even when donors have passed screening criteria, milk banks still discard any batches of milk that fail to pass culture standards post-pasteurization [44] .
Human Milk Analysis
With the concerns outlined above regarding nutritional quality of donor human milk and with the recent availability of technology to perform real time human milk analysis, it is becoming possible to evaluate donor milk for macronutrient content (protein, fat, lactose).
Analyzers are generally of two types, based on the light spectrum used: near infrared and mid-infrared. Each has been used by the dairy industry for years to monitor milk quality of their herds. These instruments are now being adapted to provide macronutrient analysis of human milk. Each type of instrument is calibrated based on multiple samples of human milk which have been analyzed in certified chemical laboratories (i.e., DQCI Laboratories, Mounds View, MN; http://www.dqci.com/) for each compound. The results of these tests are then used to adjust the computer models that convert spectrophotometric data into quantitative results.
Mid-infrared (MIR) spectroscopy is the certified method of the Association of Analytical Communities for dairy milk macronutrient analysis [45] . The instrumentation includes a light source with filters that allow the transmission of specific wavelengths through a cuvette or flow cell, and a detector. Vibrations in the MIR spectrum are associated with defined functional groups, which directly correlate to fat (C-H in the fatty acid chains), protein (peptide linkages between amino acids), and lactose (O-H) [46] [47] [48] . The transmitted values are converted to concentrations (g/dL) by the specific calibration models for each macronutrient. Energy is a calculation based on accepted values of 9 kcal/gm for fat and 4 kcal/gram each for protein and carbohydrate. There are also devices that use the near-infrared spectrum for their analyses.
Fortification
Nutritional goals for the management of the VLBW infant are to promote appropriate lean body growth (similar to that of the in utero fetus at the comparable gestational age) and avoid postnatal growth failure and/or metabolic stress. This requires a balance between energy and protein with adequate amounts of each provided to support the developmental stage of the infant. Earlier in this paper, the limitations of unfortified human milk (either mother's own milk or, especially, donor human milk) to support this rapid period of growth have been described. Thus, fortification is routine in the NICU but, given the differences between preterm milk and donor human milk, the amount of fortifier may need to be adjusted to make up for those differences. In 2014, the options for fortifying human milk products are more varied than ever before. Powder formulas and fortifiers are no longer recommended for VLBW infants due to the risk of contamination and subsequent bacteremia [49, 50] . Concentrated, bovine milk-based sterile liquid fortifiers are available from commercial companies (Similac Human Milk Fortifier, Abbott Nutrition, Columbus, OH and Human Milk Fortifier Acidified Liquid, Mead Johnson Nutrition, Evansville, IN). In addition, there is a fortifier derived from human milk (Prolacta Bioscience, Monrovia, CA) which enables a baby to receive a complete human milk diet. These products are added to human milk primarily to boost protein and mineral content ( Table 1) .
Fortification can be managed in three ways:
• Standard: the amount of added fortifier is the same for all infants
• Adjustable: the amount of fortifier is adjusted based on a surrogate marker of protein nutriture (i.e. BUN)
• Individualized or targeted: the amount of fortifier is adjusted after poor infant growth and/or results from analysis of the milk show the inadequacy of nutrients Standard fortification is based on an assumed average nutrient content of native milk despite the acknowledged variability between preterm and term human milk [51] [52] [53] [54] [55] [56] as well as effects of storage and processing (Fig. 1) . With this approach, fortification is the same for all infants.
Adjustable fortification was described by Arslanoglu et al. [57] . The investigators used BUN as their signal for making adjustments (either more or less fortifier). In a follow-up article [58] , the authors found that when the milk-fortifier mixtures were tested, protein content was consistently lower than assumed even though fat and energy content showed smaller differences between actual and assumed concentrations which were not statistically different. The variability of protein content was judged to be due to the inherent differences between milk samples, especially with donor human milk.
Targeted fortification takes into consideration the adequacy of the recent growth rate of the infant on the current fortified human milk and macronutrient analysis of the milk that is being supplied to the infant. VLBW infants need to gain at least 18 g/kg/day to experience catch-up growth and avoid postnatal growth failure [59] . If an infant is being fed mother's own milk, the milk will likely start out with a higher protein content in the early lactation period but then falls over the first weeks after birth. Donor milk almost always comes from women delivering at term and will need additional supplementation to support the desired growth in the VLBW infant.
Conclusions
Mother's milk is the preferred form of nutrition for premature infants. However, mother's milk may be inadequate as a sole diet due to insufficient production, restricted volume intake for some infants, and/or insufficient nutrient quality for the VLBW infant. If the maternal supply is insufficient to meet the infant's needs, pasteurized fortified donor milk can be used as a supplement. Preterm formula may be used if neither source of human milk is available. No donor human milk should be provided outside of the organization of an established human milk bank or provider. This assures adequate screening of donors and pasteurization of the donor human milk. Donor human milk must be fortified to meet the nutritional requirements for the VLBW infant and, especially, infants \1,000 g birth weight. This will achieve better short-term growth, which is associated with improved neurocognitive outcome.
Individualized or targeted fortification is becoming available. This allows the individual variability in human milk from mother to mother and the inadequacies of the donor milk pool to be specifically addressed with multinutrient fortifiers and individual modular supplements.
A recent provocative article addresses the need to increase the global supply and affordability of donor milk [16] . The challenges are many and will require new innovative strategies and products to meet the demands of providing human milk for all VLBW infants.
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